Sign up for our Oncology Central weekly news round-up

Coffee Chat: Best practice in managing the unique needs of non-viral HCC

This Coffee Chat has been initiated & funded by Eisai Europe Ltd

Discover the latest evidence and clinical experience on best practices for managing the unique needs of non-viral hepatocellular carcinoma (HCC) patients.

Register for our exclusive Coffee Chat focusing on non-viral HCC. This informal discussion, filmed at the ESMO 2023 Congress (20–24 October 2023, Madrid, Spain) explores the current management of people with non-viral HCC as well as the challenges associated with the clinical management of the disease.

Hosted by Rachel Jenkins (Oncology Central), the conversation features two experts who have a passion for advancing clinical practice for HCC patients: Andrea Casadei Gardini (Università Vita-Salute San Raffaele, Milan, Italy) and David J Pinato (Imperial College, London).

What will you learn?Who may this interest?Speakers

What will you learn?

  • What is the current pathway for managing non-viral HCC?
  • How does the prognosis of people with non-viral HCC compare to viral causes of HCC?
  • What challenges do we face in the management of people with non-viral HCC?
  • Do people with non-viral HCC have unique needs compared to people with viral HCC?
  • What can we expect in the next 5-10 years?

Who this may interest?

  • Clinical Oncologists
  • Translational researchers
  • Surgeons

Speakers

Dr David J Pinato

Consultant Medical Oncologist & Clinician Scientist

Imperial College London (UK)

Dr David J. Pinato is a Clinician Scientist and Consultant Medical Oncologist working within the Department of Surgery and Cancer at Imperial College, London.
In 2018 David was awarded a fellowship funded by the Wellcome Trust Strategic Fund, and leads a translational research program on early implementation of experimental therapies including studies of immune checkpoint inhibitors in liver cancer. David’s studies have led to the qualification of novel prognostic and predictive biomarkers in hepatocellular carcinoma (HCC), published in leading journals.
David’s work on biomarkers earned him the Merit Award from the American Society of Clinical Oncology (ASCO) in 2016, 2017 & 2019. In 2019 he obtained another Merit Award from ASCO and the Society for Immunotherapy of Cancer, and the ASCO Global Oncology Young Investigator Award for HIV-associated HCC research.

Prof Andrea Casadei Gardini

Associate Professor of Medical Oncology

University Vita-Salute San Raffaele (Milan, Italy)

Prof Andrea Casadei Gardini is Head of liver cancer at San Raffaele Research Hospital and Associate Professor at the Vita-Salute San Raffaele University in Milan.
Andrea graduated in 2008, but his post-graduate education continued with a Medical Oncology degree in 2013 and a liver Fellowship in 2017.
He is a member of the AIOM Guidelines Writing Committee on hepatocellular carcinoma (HCC), and his main area of interest is treatment of gastrointestinal tumours particularly cholangiocarcinoma and HCC, authoring over 220 experimental and clinical articles in these areas.
Since 2015 Andrea has presented at several international conferences including the American Society of Clinical Oncology’s Gastrointestinal Symposium, the International Liver Cancer Association meeting and the HCC-summit of the European Association for the Study of the Liver.

Initiated & funded by Eisai Europe Ltd